Dry Eye Syndrome Market Research Report 2023
Dry Eye Syndrome Market Size By Product Type (Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues, Others), End-User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Pharmacies) and Region Global Market Analysis and Forecast, 2023-2030
Dry Eye Syndrome Market Synopsis
The Global Dry Eye Syndrome Market size was reasonably estimated to be approximately USD 2,985.99 Million in 2023 and is poised to generate revenue over USD 4,868.04 Million by the end of 2030, projecting a CAGR of around 6.30% from 2023 to 2030.
The Dry Eye Syndrome Market refers to the global market for products and services related to the diagnosis, treatment, and management of dry eye syndrome. Dry eye syndrome, also known as dry eye disease or keratoconjunctivitis sicca, is a common eye condition characterized by insufficient tear production, poor tear quality, or a combination of both. It leads to symptoms such as dryness, discomfort, redness, itching, and blurred vision.
- There are two primary types of dry eye syndrome: Aqueous-deficient dry eye: This type occurs when the lacrimal glands fail to produce enough tears to keep the eyes adequately lubricated. It can result from various factors, including autoimmune diseases, hormonal changes), certain medications, and systemic conditions.
- Evaporative dry eye: This type is more common and occurs when the tears evaporate too quickly due to abnormalities in the lipid (oil) layer of the tear film. The lipid layer is produced by the meibomian glands located in the eyelids. Dysfunction of these glands, often caused by meibomian gland dysfunction (MGD), can lead to evaporative dry eye.
- Treatment for dry eye syndrome aims to relieve symptoms, improve tear production and quality, and protect the ocular surface. This can involve the use of artificial tears or lubricating eye drops, prescription medications (such as anti-inflammatory drugs or immunosuppressants), lifestyle modifications (such as reducing screen time or using humidifiers), and in some cases, procedures or surgeries to address underlying causes or improve tear retention.
Source – Statista
Top Key Players Involved Are:
"Novartis AG (Switzerland), AbbVie Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Santen Pharmaceutical Co. Ltd. (Japan), AFT Pharmaceuticals (New Zealand), Johnson & Johnson Services Inc. (US), Otsuka Pharmaceutical Co. Ltd. (Japan), OASIS Medical (US), Oyster Point Pharma Inc. (US), Bausch & Lomb (US), Alcon (Switzerland), Sentiss Pharma Pvt. Ltd. (India), VISUfarma (Netherlands), I-Med Pharma Inc. (Canada), Allostera Pharma (US), Acadia Pharmaceuticals (US), Valent Pharmaceuticals (US), Takeda Pharmaceutical Company Limited (Ireland), Kala Pharmaceuticals (US), Nicox S.A. (France), and Other Major Players."
Dry Eye Syndrome Market Trend Analysis
Increasing Prevalence of Dry Eye Syndrome
- The increasing prevalence of dry eye syndrome (DES) is a significant driver for the dry eye syndrome market. There has been a noticeable rise in the number of people affected by DES, attributed to various factors such as aging populations, increased screen time, environmental conditions, and lifestyle changes.
- The expanding population of individuals suffering from DES creates a larger target market for pharmaceutical companies and medical device manufacturers. This drives investments in research and development to develop innovative therapies and products specifically tailored to address the symptoms and underlying causes of dry eye syndrome.
- The driver of increasing prevalence creates a favorable market environment where there is a consistent demand for dry eye syndrome treatments, including artificial tears, lubricants, prescription medications, and medical devices.
- Hence, the rising prevalence of dry eye syndrome serves as a critical driver for the dry eye syndrome market, prompting the development of new treatments, improving diagnostic capabilities, and fostering greater awareness and proactive management of this condition.
Development of Novel Therapies
- The development of novel therapies presents a significant opportunity in the dry eye syndrome (DES) market. Ongoing research and innovation focused on finding new treatment approaches for DES offer the potential for improved patient outcomes and expanded treatment options.
- The current landscape of DES treatment mainly involves the use of artificial tears, lubricants, and prescription medications. However, there is a need for more effective and targeted therapies to address the underlying causes of DES and alleviate its symptoms.
- The opportunity lies in the exploration and development of innovative drug formulations, such as new lubricants, anti-inflammatory agents, and regenerative medicine approaches.
- In conclusion, the development of novel therapies represents a significant opportunity in the DES market. By addressing the underlying causes of DES and providing more effective symptom relief, these innovative treatments have the potential to transform patient care and improve the quality of life for individuals suffering from this chronic condition.
Segmentation Analysis of Dry Eye Syndrome Market
- Dry Eye Syndrome Market segments covers the Product Type, End-User, and Distribution Channel. By Product Type, the Artificial Tears segment is Anticipated to Dominate the Market Over the Forecast period.
- Artificial tears are widely used as a first-line treatment for DES, providing lubrication and moisture to the eyes to alleviate symptoms of dryness, irritation, and discomfort. Artificial tears are available in various formulations, including preservative-free and those containing additives to improve tear film stability.
- Furthermore, the continuous product advancements in the artificial tears segment, such as the development of preservative-free formulations and those with improved viscosity and stability, enhance patient comfort and satisfaction.
- In conclusion, the Artificial Tears segment is anticipated to dominate the DES market in the forecast period due to its wide availability, ease of access, and effectiveness in providing symptomatic relief for dry eye symptoms.
Regional Analysis of the Dry Eye Syndrome Market
Asia Pacific is Expected to Dominate the Market Over the Forecast Period.
- The region has a large and rapidly growing population, including a significant aging population. Age is a key risk factor for DES, and the increasing number of elderly individuals in Asia Pacific drives the prevalence of DES in the region.
- Also, lifestyle factors and environmental conditions in many countries within the Asia Pacific, such as high levels of air pollution, dry climates, and extensive use of digital devices, contribute to the higher incidence of DES.
- Furthermore, the increasing disposable incomes and improving healthcare infrastructure in many countries within Asia Pacific enable greater accessibility to healthcare services, including DES diagnosis and treatment options.
- In conclusion, the Asia Pacific region is expected to dominate the DES market over the forecast period due to factors such as the large and growing population, lifestyle and environmental factors contributing to DES prevalence, increasing healthcare accessibility, and the presence of key market players.
Covid-19 Impact Analysis on Dry Eye Syndrome Market
- The COVID-19 pandemic has had a noticeable impact on the dry eye syndrome (DES) market. The pandemic led to disruptions in healthcare services globally, including routine eye examinations and non-urgent visits.
- During the pandemic, healthcare systems and providers were primarily focused on managing COVID-19 cases. As a result, non-urgent conditions such as DES might have received less attention, leading to a temporary decline in diagnosis rates and treatment initiation.
- With the widespread adoption of remote work and increased screen time during lockdowns, individuals were exposed to prolonged periods of digital device use. This shift in lifestyle and working conditions could have contributed to an exacerbation of DES symptoms and an increased demand for treatment options.
- In conclusion, the COVID-19 pandemic has posed challenges to the DES market, primarily due to disruptions in healthcare services, changes in lifestyle and working conditions, and supply chain disruptions. However, it has also brought attention to the importance of eye health and self-care practices.
Top Key Players Covered in Dry Eye Syndrome Market
- Novartis AG (Switzerland)
- AbbVie Inc. (US)
- Sun Pharmaceutical Industries Ltd. (India)
- Santen Pharmaceutical Co. Ltd. (Japan)
- AFT Pharmaceuticals (New Zealand)
- Johnson & Johnson Services Inc. (US)
- Otsuka Pharmaceutical Co. Ltd. (Japan)
- OASIS Medical (US)
- Oyster Point Pharma Inc. (US)
- Bausch & Lomb (US)
- Alcon (Switzerland)
- Sentiss Pharma Pvt. Ltd. (India)
- VISUfarma (Netherlands)
- I-Med Pharma Inc. (Canada)
- Allostera Pharma (US)
- Acadia Pharmaceuticals (US)
- Valent Pharmaceuticals (US)
- Takeda Pharmaceutical Company Limited (Ireland)
- Kala Pharmaceuticals (US)
- Nicox S.A. (France), and Other Major Players.
Key Industry Developments in Dry Eye Syndrome Market
In November 2022, Santen Pharmaceutical Co. Ltd. announced the successful launch of DIQUAS® LX Ophthalmic Solution 3% (diquafosol sodium) in Japan for the treatment of the dry eye. The launch of this new treatment option demonstrates Santen's commitment to addressing the needs of individuals suffering from dry eye, a condition that can cause discomfort and visual disturbances.
In February 2022, Contract sales organization Farmaforce officially partnered with AFT Pharmaceuticals to deliver exceptional representation to healthcare practitioners in Australia. Through this collaboration, Farmaforce strengthened AFT's presence in the Australian market by promoting a range of AFT health products to practitioners.
|
Global Dry Eye Syndrome Market |
|||
|
Base Year: |
2022 |
Forecast Period: |
2023-2030 |
|
Historical Data: |
2016 to 2021 |
Market Size in 2023: |
USD 2,985.99 Mn. |
|
Forecast Period 2023-30 CAGR: |
6.30% |
Market Size in 2030: |
USD 4,868.04 Mn. |
|
Segments Covered: |
By Product Type |
|
|
|
By End-User |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Global Dry Eye Syndrome Market |
|||
|
Base Year: |
2022 |
Forecast Period: |
2023-2030 |
|
Historical Data: |
2016 to 2021 |
Market Size in 2023: |
USD 2,985.99 Mn. |
|
Forecast Period 2023-30 CAGR: |
6.30% |
Market Size in 2030: |
USD 4,868.04 Mn. |
|
Segments Covered: |
By Product Type |
|
|
|
By End-User |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the Report: |
|
||
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Product Type
3.2 By End-User
3.3 By Distribution Channel
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory
Frequently Asked Questions
What would be the forecast period in the Dry Eye Syndrome Market research report?
The forecast period in the Dry Eye Syndrome Market research report is 2023-2030.
Who are the key players in Dry Eye Syndrome Market?
Novartis AG (Switzerland), AbbVie Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Santen Pharmaceutical Co. Ltd. (Japan), AFT Pharmaceuticals (New Zealand), Johnson & Johnson Services Inc. (US), Otsuka Pharmaceutical Co. Ltd. (Japan), OASIS Medical (US), Oyster Point Pharma Inc. (US), Bausch & Lomb (US), Alcon (Switzerland), Sentiss Pharma Pvt. Ltd. (India), VISUfarma (Netherlands), I-Med Pharma Inc. (Canada), Allostera Pharma (US), Acadia Pharmaceuticals (US), Valent Pharmaceuticals (US), Takeda Pharmaceutical Company Limited (Ireland), Kala Pharmaceuticals (US), Nicox S.A. (France), and Other Major Players.
What are the segments of the Dry Eye Syndrome Market?
The Dry Eye Syndrome Market is segmented into Product Type, End-User, Distribution Channel, and Region. By Product Type, the market is categorized into Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues, Others. By End-User, the market is categorized into Hospitals, Specialty Clinics, Homecare, Others. By Distribution Channel, the market is categorized into Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Pharmacies. By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia Pacific (China; India; Japan; South Korea; Malaysia; Thailand; Vietnam; The Philippines; Australia; New-Zealand; Rest of APAC), Middle East & Africa (Turkey; Bahrain; Kuwait; Saudi Arabia; Qatar; UAE; Israel; South Africa), South America (Brazil; Argentina; Rest of SA)
What is the Dry Eye Syndrome Market?
The Dry Eye Syndrome Market refers to the global market for products and services related to the diagnosis, treatment, and management of dry eye syndrome. Dry eye syndrome, also known as dry eye disease or keratoconjunctivitis sicca, is a common eye condition characterized by insufficient tear production, poor tear quality, or a combination of both. It leads to symptoms such as dryness, discomfort, redness, itching, and blurred vision.
How big is the Dry Eye Syndrome Market?
The Global Dry Eye Syndrome Market size was reasonably estimated to be approximately USD 2,985.99 Million in 2023 and is poised to generate revenue over USD 4,868.04 Million by the end of 2030, projecting a CAGR of around 6.30% from 2023 to 2030.
